Egashira et al 44 (87) Retrospective High Pulmonary tumours of Adverse events Not used 2016 CS primary or secondary origind Median 15 (6.2–29.5) months He et al (2006) 12 (16) Retrospective High Primary cancer not Adverse events Not used CS suitable for resection and patients with Mean: 20 oligometastatic lung months lesions Little et al 23 (29) Retrospective High Primary cancer not Adverse events Not used (2013) CS suitable for resection and oligometastatic lung Median 6 lesions months Lu et al (2012) 69 (93) Retrospective High Stage IIIB NSCLC or Adverse events Not used CS pulmonary metastases, inoperable NR Nour-eldin et al 164e (NR) Retrospective High Primary NSCLC or Adverse events Not used (2011) CS secondary lung tumours, inoperable NR Sun et al (2014) 29 (39) Retrospective High Primary or metastatic Adverse events Not used CS lung cancer Median 25 months Splatt & Steinke 51 (70) Retrospective High Primary pulmonary Adverse events Not used (2015) CS malignancies or secondary metastases NR Vogl et al 57 (91) Retrospective High Primary or Adverse events Not used (2012) CS oligometastatic secondary lung cancer mean (range): 10.2 (6.0–29.2) months Wolf et al 82 (NR) Retrospective High Primary or secondary Adverse events Not used (2008) CS lung cancer, medically inoperable or refusing mean (SD): 10 surgery (6.8) months
Egashira et al 2016 44 (87) Retrospective CS Median 15 (6.2–29.5) months High Pulmonary tumours of primary or secondary origind Adverse events Not used He et al (2006) 12 (16) Retrospective CS Mean: 20 months High Primary cancer not suitable for resection and patients with oligometastatic lung lesions Adverse events Not used Little et al (2013) 23 (29) Retrospective CS Median 6 months High Primary cancer not suitable for resection and oligometastatic lung lesions Adverse events Not used Lu et al (2012) 69 (93) Retrospective CS NR High Stage IIIB NSCLC or pulmonary metastases, inoperable Adverse events Not used Nour-eldin et al (2011) 164e (NR) Retrospective CS NR High Primary NSCLC or secondary lung tumours, inoperable Adverse events Not used Sun et al (2014) 29 (39) Retrospective CS Median 25 months High Primary or metastatic lung cancer Adverse events Not used Splatt & Steinke (2015) 51 (70) Retrospective CS NR High Primary pulmonary malignancies or secondary metastases Adverse events Not used Vogl et al (2012) 57 (91) Retrospective CS mean (range): 10.2 (6.0–29.2) months High Primary or oligometastatic secondary lung cancer Adverse events Not used Wolf et al (2008) 82 (NR) Retrospective CS mean (SD): 10 (6.8) months High Primary or secondary lung cancer, medically inoperable or refusing surgery Adverse events Not used
1403%20-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx